Page last updated: 2024-11-01

niceritrol and Chronic Disease

niceritrol has been researched along with Chronic Disease in 2 studies

Niceritrol: An ester of nicotinic acid that lowers cholesterol and triglycerides in total plasma and in the VLD- and LD-lipoprotein fractions.

Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).

Research Excerpts

ExcerptRelevanceReference
" We administered niceritrol, a nicotinic acid derivative, to patients with chronic renal disease and a high serum Lp(a) level, and studied its effects on lipid metabolism, proteinuria, and renal function."5.10Antiproteinuric effect of niceritrol, a nicotinic acid derivative, in chronic renal disease with hyperlipidemia: a randomized trial. ( Hata, T; Owada, A; Suda, S, 2003)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bostom, AG1
Owada, A1
Suda, S1
Hata, T1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Randomized, Double-blind, Placebo-controlled Trial of NiaspanĀ® in Patients With Overt Diabetic Nephropathy and Moderate Renal Impairment[NCT00108485]Phase 39 participants (Actual)Interventional2005-04-30Terminated (stopped due to Unable to recruit sufficient study subjects)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Proteinuria

(NCT00108485)
Timeframe: Baseline, 1 year

Interventionmg/dL (Number)
Extended Release Niacin42
Placebo63

Trials

1 trial available for niceritrol and Chronic Disease

ArticleYear
Antiproteinuric effect of niceritrol, a nicotinic acid derivative, in chronic renal disease with hyperlipidemia: a randomized trial.
    The American journal of medicine, 2003, Apr-01, Volume: 114, Issue:5

    Topics: Chronic Disease; Creatinine; Disease Progression; Female; Humans; Hyperlipidemias; Hypolipidemic Age

2003

Other Studies

1 other study available for niceritrol and Chronic Disease

ArticleYear
Binder blinders-niacin of omission?
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2010, Volume: 55, Issue:4

    Topics: Animals; Cardiovascular Diseases; Chronic Disease; Clinical Trials as Topic; Humans; Hyperphosphatem

2010